KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Payables (2017 - 2025)

Amneal Pharmaceuticals has reported Payables over the past 9 years, most recently at $38.8 million for Q4 2025.

  • Quarterly results put Payables at $38.8 million for Q4 2025, up 3122.57% from a year ago — trailing twelve months through Dec 2025 was $38.8 million (up 3122.57% YoY), and the annual figure for FY2025 was $38.8 million, up 3122.57%.
  • Payables for Q4 2025 was $38.8 million at Amneal Pharmaceuticals, up from $40000.0 in the prior quarter.
  • Over the last five years, Payables for AMRX hit a ceiling of $666.8 million in Q2 2025 and a floor of $2000.0 in Q2 2024.
  • Median Payables over the past 5 years was $525.3 million (2021), compared with a mean of $339.2 million.
  • Biggest five-year swings in Payables: crashed 100.0% in 2024 and later surged 33340750.0% in 2025.
  • Amneal Pharmaceuticals' Payables stood at $525.3 million in 2021, then grew by 10.0% to $577.9 million in 2022, then crashed by 92.83% to $41.4 million in 2023, then plummeted by 97.09% to $1.2 million in 2024, then soared by 3122.57% to $38.8 million in 2025.
  • The last three reported values for Payables were $38.8 million (Q4 2025), $40000.0 (Q3 2025), and $666.8 million (Q2 2025) per Business Quant data.